Vivek Ramaswamy
Chief Executive Officer
biotechnology
Roivant Sciences
Switzerland
Biography
Vivek Ramaswamy is founder and Chief Executive Officer of the Roivant Sciences family of companies. The Roivant Sciences family includes five wholly-owned or majority-owned subsidiaries, each focused on a different disease area: Axovant (neurology), Myovant (women’s health and endocrine diseases), Enzyvant (rare diseases), Dermavant (dermatology), and Urovant (urology). The group has 14 drugs in its pipeline and has raised over $2.5 billion in capital to date to fund late-stage clinical programs and pursue adjacent business opportunities. Prior to founding Roivant, Mr. Ramaswamy was a well-known investor in the biotechnology sector. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences, Myovant Sciences, and Roivant Sciences. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.
Research Interest
biology
